CAPREIT Announces August 2025 Distribution

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) announced today its August 2025 monthly distribution in the amount of $0.12916 per Unit (or $1.55 on an annualized basis). The August 2025 distribution will be payable on September 15, 2025 to Unitholders of record at the close of business on August 29, 2025.

CAPREIT is Canada’s largest publicly traded provider of quality rental housing. As at June 30, 2025, CAPREIT owns approximately 45,400 (excluding approximately 1,600 suites classified as assets held for sale) residential apartment suites and townhomes that are well-located across Canada and the Netherlands, with a total fair value of approximately $14.5 billion (excluding approximately $0.6 billion of assets held for sale). Since its Initial Public Offering in May 1997, CAPREIT has grown monthly cash distributions per Unit by 117%. For more information about CAPREIT, its business and its investment highlights, please visit our website at www.capreit.ca and our public disclosure which can be found under our profile at www.sedarplus.ca.

For further information please contact:

CAPREIT Mr. Mark Kenney President & Chief Executive Officer (416) 861-9404

CAPREIT Mr. Stephen Co Chief Financial Officer (416) 306-3009

CAPREIT Mr. Julian Schonfeldt Chief Investment Officer (647) 535-2544

Source: Canadian Apartment Properties Real Estate Investment Trust

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual
• Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
• Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)